Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aehr Test Systems (AEHR) vs GeneDx Holdings Corp (WGS) Price & Performance

Aehr Test SystemsTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Aehr Test Systems vs GeneDx Holdings Corp — how do they compare? Aehr Test Systems trades at $129.02 (market cap $3.82B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Aehr Test Systems is the larger of the two by market cap, and Aehr Test Systems is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

AEHRWGS
Market Cap
$3.82B$2.44B
Sector
TechnologyTechnology
52-Week High
$117.18$167.51
52-Week Low
$17.38$34.51
Enterprise Value
$3.72B$2.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aehr Test Systems

Aehr Test Systems (AEHR) trades at $129.23, up 21.69% in the last 24 hours, reflecting strong momentum. The stock is technically bullish, trading near resistance at $129, with a high RSI suggesting potential overbought conditions. Fundamentally, the company reported a net loss of $3.91 million for 2025, but has beaten EPS estimates for three consecutive quarters. Recent news highlights a $22 million follow-on order for AI processor wafer-level burn-in systems, signaling robust demand in high-growth sectors.

The outlook is supported by record bookings and a strategic pivot to AI infrastructure, though high valuation multiples and insider selling pose risks. Revenue growth guidance of 160-200% for FY27 offers significant upside potential, but investor caution is warranted due to customer concentration and current unprofitability.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.

Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aehr Test Systems

Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.

Read more on AEHR

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS